miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Centers for Disease Control and Prevention. Basic Information About Gynecologic Cancers (last revised 16 August 2021). www.cdc.gov/cancer/gynecologic/basic_info/index.htm
  Google Scholar
• 2. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 3. Deng NA, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 8(66), 110635–110649 (2017). •• Illustrates many genetic and epigenetic pathways involved in predicting cancer risk associated with specific SNPs found in found in the 5′ and 3′ untranslated regions, exons, introns and promoters of genes; discusses the diagnostic importance of these SNPs.
  MedlineGoogle Scholar
• 4. Mahjabeen I, Maqsood Y, Abbasi R et al. Polymorphism in miRNA target sites of CEP-63 and CEP-152 ring complex influences expression of CEP genes and favors tumorigenesis in glioma. Future Oncol. 17(25), 3355–3372 (2021).
  CASGoogle Scholar
• 5. Masood Y, Shal M, Shah MF et al. Dysregulated expression of microRNAs acts as prognostic and diagnostic biomarkers for glioma patients. Mol. Genet. Genom. 297(5), 1389–1401 (2022).
  Medline CASGoogle Scholar
• 6. Zining J, Lu X, Caiyun H, Yuan Y. Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis. Oncotarget. 7(35), 57464–57480 (2016).
  MedlineGoogle Scholar
• 7. Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 10(1), 1–11 (2020).
  Medline CASGoogle Scholar
• 8. Rad E, Murray JT, Tee AR. Oncogenic signalling through mechanistic target of rapamycin (mTOR): a driver of metabolic transformation and cancer progression. Cancers. 10(1), 5 (2018).
  MedlineGoogle Scholar
• 9. Cao Q, Ju X, Li P et al. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk. PLOS ONE. 7(11), e50302 (2012). • Investigates the relationship between renal carcinoma risk and genetic polymorphisms in genes relevant to the mTOR pathway. Functional mTOR promoter variant rs2295080 influences the level of endogenous mTOR expression, which in turn influences renal carcinoma susceptibility.
  Medline CASGoogle Scholar
• 10. He J, Wang MY, Qiu LX et al. Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern Chinese population. Mol. Carcinog. 52(Suppl. 1), 70–79 (2013).
  Medline CASGoogle Scholar
• 11. Qi L, Sun K, Zhuang Y et al. Study on the association between PI3K/AKT/mTOR signaling pathway gene polymorphism and susceptibility to gastric cancer. J buon. 22(6), 1488–1493 (2017).
  MedlineGoogle Scholar
• 12. Zhang Z, Chen Q, Zhang J et al. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: a meta-analysis in Asian population. Sci Rep. 7(1), 1–11 (2017).
  MedlineGoogle Scholar
• 13. Li Q. Functional genetic variants in the mTORC1 related genes contribute to prostate cancer susceptibility and clinical outcomes (PhD Thesis). Fudan University, Shanghai, China (2014).
  Google Scholar
• 14. Zhang Z, Chen Q, Zhang J et al. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: a meta-analysis in Asian population. Sci. Rep. 7(1), 1–11 (2017). • Demonstrates genetic risk factors, core gene polymorphisms in the PTEN/AKT/mTOR pathway association with cancer susceptibility and the most reliable assessment of cancer prevalence in the Asian population.
  MedlineGoogle Scholar
• 15. Bo YY, Liang LD, Hua YJ et al. High-purity DNA extraction from animal tissue using picking in the TRIzol-based method. Biotechniques. 70(3), 186–190 (2021).
  Medline CASGoogle Scholar
• 16. Mahjabeen I, Sheshe S, Shakoor T et al. Role of genetic variations of DNA damage response pathway genes and heat-shock proteins in increased head and neck cancer risk. Future Oncol. 18(31), 3519–3535 (2022).
  CASGoogle Scholar
• 17. Esserman LJ, Thompson IM, Reid B et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 15(6), e234–e242 (2014).
  MedlineGoogle Scholar
• 18. Maheshwari A, Kumar N, Mahantshetty U. Gynecological cancers: a summary of published Indian data. South Asian J. Cancer. 5(03), 112–120 (2016).
  MedlineGoogle Scholar
• 19. Wang Y, Luo J, Zhang H, Lu J. microRNAs in the same clusters evolve to coordinately regulate functionally related genes. Mol. Biol. Evol. 33(9), 2232–2247 (2016).
  Medline CASGoogle Scholar
• 20. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer. 15(6), 321–333 (2015).
  Medline CASGoogle Scholar
• 21. Gilabert-Estelles J, Braza-Boils A, Ramon LA. Role of microRNAs in gynecological pathology. Curr. Med. Chem. 19(15), 2406–2413 (2012). •• Reports on various human cancers, including endometrial, cervical and ovarian cancer; discusses aberrant miRNA expression and that certain dysregulated miRNAs may serve as indicators for patient prognosis.
  Medline CASGoogle Scholar
• 22. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 95(11), 866–871 (2004).
  Medline CASGoogle Scholar
• 23. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. BioMed Res. Int. 2013, 11 (2013).
  Google Scholar
• 24. Rebbeck TR, Mitra N, Wan F et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 313(13), 1347–1361 (2015).
  Medline CASGoogle Scholar
• 25. Simons CC, Schouten LJ, Godschalk RW et al. Polymorphisms in the mTOR-PI3K-Akt pathway, energy balance-related exposures and colorectal cancer risk in the Netherlands Cohort Study. Bio Data Mining. 15(1), 1–20 (2022).
  Google Scholar
• 26. Zhao Y, Diao Y, Wang X et al. Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population. Oncotarget. 7(36), 58174–58180 (2016). • Reports a correlation between mTOR polymorphisms and the risk of breast cancer. The rs2536 polymorphism had no association with breast cancer risk, whereas the rs2295080 polymorphism was linked to a lower risk of breast cancer in a Chinese sample.
  MedlineGoogle Scholar
• 27. Cheng L, Qiu L, Zhang R et al. Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients. Int. J. Cancer. 144(2), 251–262 (2019).
  Medline CASGoogle Scholar
• 28. Zhu ML, Yu H, Shi T et al. Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations. J. Thorac. Oncol. 8(6), 788–795 (2013).
  Medline CASGoogle Scholar
• 29. Chen J, Shao P, Cao Q et al. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLOS ONE. 7(7), e40817 (2012).
  Medline CASGoogle Scholar
• 30. Shao J, Li Y, Zhao P et al. Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis. PLOS ONE. 9(5), e97085 (2014). • Evaluates the relationship between mTOR polymorphisms (rs2295080, rs2536 and rs11121704) and clinical outcome. The mTOR polymorphisms (rs2295080 and rs11121704) were associated with cancer risk.
  MedlineGoogle Scholar
• 31. Qi GH, Wang CH, Zhang HG et al. Comprehensive analysis of the effect of rs2295080 and rs2536 polymorphisms within the mTOR gene on cancer risk. Biosci. Rep. 40(7), BSR20191825 (2020).
  Medline CASGoogle Scholar
• 32. Knox B, Wang Y, Rogers LJ et al. A functional SNP in the 3′-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression. Environ. Mol. Mutagen. 59(2), 134–143 (2018).
  Medline CASGoogle Scholar
• 33. Wang X, Tang S, Le SY et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLOS ONE. 3(7), e2557 (2008).
  MedlineGoogle Scholar
• 34. Shotan A, Widerhorn J, Hurst A et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am. J. Med. 96(5), 451–456 (1994).
  Medline CASGoogle Scholar
• 35. Song YH, Shao L, Zhang Y et al. Exosomes derived from embryonic stem cells as potential treatment for cardiovascular diseases. Exosomes Cardiovasc. Dis. 998, 187–206 (2017).
  CASGoogle Scholar
• 36. Sun S, Wang X, Xu X et al. MiR-433-3p suppresses cell growth and enhances chemosensitivity by targeting CREB in human glioma. Oncotarget. 8(3), 5057 (2017).
  MedlineGoogle Scholar
• 37. Liang T, Guo Q, Li L et al. MicroRNA-433 inhibits migration and invasion of ovarian cancer cells via targeting Notch1. Neoplasma. 63(5), 696–704 (2016).
  Medline CASGoogle Scholar
• 38. Zhang J, Xu S, Xu J et al. miR-767-5p inhibits glioma proliferation and metastasis by targeting SUZ12. Oncol. Rep. 42(1), 55–66 (2019). •• Evaluated MiR-767-5p in glioblastoma (GBM) tissues compared with normal brain tissues and in 6 GBM cell lines compared with normal human astrocytes. miR-767-5P was found upregulated. miR767-5p reduced proliferation and colon growth when expressed erratically.
  Medline CASGoogle Scholar
• 39. Keller A, Leidinger P, Gislefoss R et al. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol. 8(3), 506–516 (2011).
  Medline CASGoogle Scholar
• 40. Zhang XB, Lin XL, Wu XY et al. Differential expression of microRNAs in xenografted Lewis lung carcinomas subjected to intermittent hypoxia: a next-generation sequence analysis. Transl. Cancer. Res. 9(7), 4354 (2020).
  Medline CASGoogle Scholar
• 41. Zhang K, Guo L. MiR-767 promoted cell proliferation in human melanoma by suppressing CYLD expression. Gene. 641, 272–278 (2018). •• Reports miR-767 as a tumor promoter by targeting CYLD in human melanoma that might serve as a prognostic or therapeutic target for human melanoma.
  Medline CASGoogle Scholar
• 42. Loriot A, Van Tongelen A, Blanco J et al. A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics. 9(8), 1163–1171 (2014).
  MedlineGoogle Scholar